[Combination chemotherapy with docetaxel+carboplatin in the treatment of cancer of the ovary and fallopian tube].

Docetaxel and carboplatin were used as adjuvant chemotherapy or maintenance chemotherapy for cancer of the ovary and fallopian tube. Docetaxel 70 mg/m2 and carboplatin (area under the concentration-versus-time curve of 5) were administered intravenously every 3 weeks. Thirty-two patients (median age, 54 years) were assessable. We had objective responses from 5 of 7 (70%) assessable patients. Our toxicity findings included the following: grade 3 or 4 neutropenia (70% of courses); grade 3 or 4 leucocytopenia (35% of courses); hypersensitive reaction (25% of patients, none requiring discontinuation of therapy): edema (30% of patients): peripheral neuropathy (6% of patients). The combination of docetaxel and carboplatin is highly active in cancer of the ovary and follapian tube. The adverse effect was significant neutropenia, but peripheral neuropathy was rare. This regimen represents a reasonable first-line option for patients with ovarian cancer.